Jacquelin B, Tuleja E, Kunicki T J, Nurden P, Nurden A T
UMR 5533 CNRS, Hôpital Cardiologique, Pessac, France.
J Thromb Haemost. 2003 Mar;1(3):573-5. doi: 10.1046/j.1538-7836.2003.00107.x.
We have tested the DNA of a large series of Glanzmann thrombasthenia patients for polymorphisms in platelet membrane glycoproteins. To our surprise, we noted a high prevalence of the HPA-1b allele of beta3, the minority allele in a normal population. This proved to be due to the presence of nine patients homozygous for the so-called French gypsy mutation (IVS15[ + 1]G-->A) in alphaIIb. Seven of these patients were homozygous for the HPA-1b alloantigen and the other two heterozygous HPA-1a/1b. As the alphaIIb and beta3 genes are both on chromosome 17, it is highly probable that the French gypsy mutation first arose on a chromosome encoding HPA-1b. For other adhesion receptors, no major differences were seen in the distribution of the A1, A2 and A3 alleles in the alpha2 gene, or in the Kozak or HPA-2 polymorphisms of GPIbalpha, suggesting that none of these alleles result in increased survival in Glanzmann thrombasthenia.
我们检测了大量Glanzmann血小板无力症患者的DNA,以寻找血小板膜糖蛋白的多态性。令我们惊讶的是,我们发现β3的HPA-1b等位基因(正常人群中的少数等位基因)的患病率很高。事实证明,这是由于存在9名αIIb基因中所谓法国吉普赛突变(IVS15[+1]G→A)纯合的患者。其中7名患者为HPA-1b同种抗原纯合子,另外两名患者为HPA-1a/1b杂合子。由于αIIb和β3基因都位于17号染色体上,很可能法国吉普赛突变最初出现在编码HPA-1b的染色体上。对于其他黏附受体,在α2基因的A1、A2和A3等位基因分布中,或在GPIbalpha的Kozak或HPA-2多态性中,未观察到主要差异,这表明这些等位基因均不会导致Glanzmann血小板无力症患者的生存率增加。